Baxalta Gmbh

Baxter International Inc.

Takeda Pharmaceutical Company Limited

Balxalta Gmbh

Baxter Healthcare Sa

Sharon Pokropinski

Francisco M Rausa

William Howard Frey, Ii

Leah Ranae Bresin Hanson

Julian P Breillatt, Jr

William H Frey

The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.

Treatment of central nervous system disorders by intranasal administration of immunoglobulin G

Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

The invention provides a leukodepletion filter including a plurality of glass fiber filter pads, and a plurality of non-woven polyester fiber filter pads, sealed within a filter housing.

Filtration media for filtering leukocytes from freshly drawn blood

A leukodepletion filter is provided including glass fiber filter pads and non-woven polyester fiber filter pads sealed within a filter housing. The filter is designed such that a fluid, such as whole blood, packed red blood cells, platelets or plasma, is conducted through the glass fiber filter pads before the non-woven polyester fiber filter pads. A method is further provided for leukodepleting a body fluid by filtering the body fluid through glass fiber filter pads and also filtering the body fluid through non-woven polyester fiber filter pads. After filtering, the body fluid is collected.

Leukodepletion filter and method for filtering leukocytes from freshly

Growing community of inventors

Schaumburg, IL, United States of America

Sharon Pokropinski